{"id":3005,"date":"2026-09-09T07:00:00","date_gmt":"2026-09-09T11:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3005"},"modified":"2026-09-12T10:36:51","modified_gmt":"2026-09-12T14:36:51","slug":"opgx-best1-shows-early-signals-in-five-treated-participants","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3005","title":{"rendered":"OPGx-BEST1 Shows Early Signals in Five Treated Participants"},"content":{"rendered":"

Evidence<\/strong> Company disclosure, corrected via SEC filing · Discovery<\/strong> September 9, 2026; corrected September 11, 2026 · Importance<\/strong> 4\/5 · Direction<\/strong> Mixed<\/p>\n

Editor’s note: This post has been updated to reflect a September 11, 2026 SEC filing in which Opus Genetics corrected an error in its original September 9 presentation of Cohort 1 visual-acuity data. The figures and analysis below reflect the corrected dataset.<\/em><\/p>\n

\"OPGx-BEST1<\/p>\n

Summary<\/h4>\n

Opus Genetics filed a revised OPGx-BEST1 presentation correcting an error in the conversion of logMAR visual acuity to ETDRS letters for the five-patient low-dose Cohort 1 of the open-label Phase I\/II BIRD-1 study in BEST1-related retinal disease. The correction changed the depicted mean best-corrected visual-acuity trajectory through three months. Corrected treated-eye changes were +12, +1, −10, +2 and +6 letters; fellow-eye changes were +4, −7, −8, −5 and +2 letters — unadjusted means of +2.2 letters for treated eyes and −2.8 for fellow eyes. Opus characterized the error as immaterial and did not revise its broader claims regarding safety, improvement in at least one functional measure for each participant, microperimetry or retinal structure.<\/p>\n

What Happened<\/h4>\n

The original September 9 presentation supported the first clinical disclosure from Cohort 1 of the BIRD-1 trial. The September 11 filing corrects the visual-acuity slide and adds high-resolution baseline and three-month microperimetry grids for each participant, including individual-locus data for three participants. The correction exposes substantial heterogeneity: one treated eye lost ten letters, while the largest treated-eye gain was twelve letters, and fellow eyes also changed in both directions. With five participants, inter-eye comparisons remain descriptive rather than statistically reliable, and mean changes can be disproportionately influenced by a single participant. Eight participants are enrolled at the higher dose, with six-month data expected in the second quarter of 2027.<\/p>\n

Deep Analysis<\/h4>\n

A multisystem signal, not a simple acuity story:<\/strong> Best-corrected visual acuity is only one component of visual function in BEST1 disease, and the company’s development thesis also relies on microperimetry, low-luminance acuity, contrast sensitivity, patient reports and structural imaging. The correction does not automatically negate the multisystem signal, but it weakens any simple narrative of uniform acuity improvement.<\/p>\n

Transparent correction, fragile small-cohort inference:<\/strong> Correcting an early conversion error through a formal SEC filing is transparent and allows independent review. The need for correction also emphasizes the fragility of conclusions drawn from very small, multiparameter cohorts. High-resolution microperimetry grids improve transparency but do not replace prespecified statistical analysis or masked assessment. Cohort 2’s higher-dose results, dose consistency, prospective endpoint definitions, patient-level concordance and durability will matter more than the corrected cohort mean.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: the conversion error affected the mean BCVA depiction through month three; corrected treated-eye changes range from a twelve-letter gain to a ten-letter loss; the filing adds higher-resolution microperimetry images. Missing facts: prespecified analytic hierarchy, confidence intervals, masked grading, test-retest variability, longer follow-up, genotype\/phenotype stratification and complete concordance across endpoints. Upgrade evidence would be reproducible higher-dose gains, treated-versus-fellow separation, microperimetry improvement in viable retinal zones, structural concordance and durability. Downgrade evidence would be additional data corrections, inconsistent direction across endpoints, absence of dose response or loss of benefit over time.<\/p>\n

Company and Product Background<\/h4>\n

Opus Genetics develops gene therapies for inherited retinal disease. OPGx-BEST1 is an adeno-associated-virus gene-replacement candidate intended to deliver functional BEST1 to retinal pigment epithelial cells in Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy.<\/p>\n

BEST1-related diseases impair ion transport and retinal-pigment-epithelium support of photoreceptors, causing fluid or vitelliform material accumulation and progressive visual dysfunction. Different genotypes and disease stages can produce heterogeneous anatomy and functional reserve.<\/p>\n

InSilens Take<\/h4>\n

This update should be treated as a material data-quality clarification, not as a new efficacy readout. It leaves the initial proof-of-concept hypothesis alive while making the uncertainty more visible: the corrected acuity response is heterogeneous and includes a substantial treated-eye decline in one participant. The scientifically appropriate focus now shifts to Cohort 2 and to endpoint concordance. A credible signal would require repeatable retinal-sensitivity and structural changes that align with patient-relevant function, persist over time and exceed fellow-eye or natural-history variability.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n4 \/ 5 — the correction affects patient-level clinical data used to support an early gene-therapy proof-of-concept claim and materially refines interpretation of the prior report<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nMixed — formal correction improves transparency, while the corrected values reveal clinically important heterogeneity and preserve substantial efficacy uncertainty<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — based on the SEC filing<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate-low — the cohort is extremely small, uncontrolled and evaluated with multiple exploratory endpoints<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Opus Genetics filed a revised OPGx-BEST1 presentation correcting an error in the conversion of logMAR visual acuity to ETDRS letters for the five-patient low-dose Cohort 1 of the open-label Phase I\/II BIRD-1 study in…<\/p>\n","protected":false},"author":1,"featured_media":3016,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[649,648,647],"class_list":["post-3005","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-best1","tag-opgx-best1","tag-opus-genetics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3005"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3005\/revisions"}],"predecessor-version":[{"id":3064,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3005\/revisions\/3064"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3016"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}